- Conditions
- Influenza
- Interventions
- AS03 Adjuvant, Phosphate Buffered Saline (PBS) diluent, Sanofi H5N1 Antigen
- Drug · Other · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 245 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Nashville, Tennessee • Houston, Texas + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 745–768
of 835
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Influenza
- Interventions
- A/turkey H5N1 vaccine, Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia), Placebo
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 841 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 10
- States / cities
- Denver, Colorado • Chicago, Illinois • Metairie, Louisiana + 7 more
- Conditions
- Rabies
- Interventions
- Active rabies vaccine (US-FDA approved)
- Drug
- Lead sponsor
- Kamada, Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 118 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Pertussis, Whooping Cough
- Interventions
- BPZE1 pertussis vaccine and VaxINator(TM) Atomization Device
- Combination Product
- Lead sponsor
- ILiAD Biotechnologies
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 3
- States / cities
- Cleveland, Ohio • Tomball, Texas • West Jordan, Utah
- Conditions
- Chronic Kidney Disease
- Interventions
- HEPLISAV-B, Engerix-B, Placebo
- Biological · Other
- Lead sponsor
- Dynavax Technologies Corporation
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 521 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Norfolk, Virginia
- Conditions
- SARS-CoV-2, Influenza, RSV
- Interventions
- mRNA-1010, mRNA-1345, mRNA-1273.214, mRNA-1045, mRNA-1230
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 392 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 14
- States / cities
- DeLand, Florida • Hollywood, Florida • St. Petersburg, Florida + 11 more
- Conditions
- Healthy Volunteers
- Interventions
- rVSV∆G-ZEBOV-GP Vaccine (V920)
- Biological
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 248 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2025
- U.S. locations
- 2
- States / cities
- Decatur, Georgia • Bethesda, Maryland
- Conditions
- Genital Herpes, HSV-2 Infection
- Interventions
- GEN-003, Matrix-M2, 0.9% normal saline
- Biological · Other
- Lead sponsor
- Genocea Biosciences, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • San Diego, California • San Francisco, California + 5 more
- Conditions
- Dermatitis, Atopic
- Interventions
- Fluzone® Intradermal Vaccine, Fluzone® (Intramuscular) vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 64 Years · Female only
- Enrollment
- 368 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 5
- States / cities
- Denver, Colorado • Chicago, Illinois • Boston, Massachusetts + 2 more
- Conditions
- Healthy Volunteers
- Interventions
- rFIV vaccine, rF1V vaccine, rF1V vaccine 160 mcg given on Study Days 0, 56, 182
- Biological
- Lead sponsor
- DynPort Vaccine Company LLC, A GDIT Company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 9
- States / cities
- Tucson, Arizona • San Francisco, California • West Palm Beach, Florida + 6 more
- Conditions
- Hemorrhagic Fever, Ebola
- Interventions
- Ad26.ZEBOV, MVA-BN-Filo, Placebo
- Biological
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 578 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Silver Spring, Maryland
- Conditions
- Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers, SARS CoV-2
- Interventions
- COMIRNATY®
- Biological
- Lead sponsor
- PharmaJet, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Decatur, Georgia
- Conditions
- Healthy Volunteers (Meningococcal Infection)
- Interventions
- MenACYW conjugate vaccine, MenACYW-135 conjugate vaccine, DTaP-IPV//Hib vaccine, Pneumococcal 13-valent conjugate vaccine, Pentavalent rotavirus vaccine, Hepatitis B vaccine, Measles, mumps, rubella (MMR) vaccine, Varicella vaccine, Hepatitis A vaccine
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 42 Days to 89 Days
- Enrollment
- 2,627 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 54 more
- Conditions
- Influenza
- Interventions
- High-Dose trivalent influenza vaccine (Split virion, Inactivated), Standard-dose trivalent influenza vaccine (Split virion, Inactivated)
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 50 Years to 64 Years
- Enrollment
- 1,180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 20
- States / cities
- Los Alamitos, California • Fort Myers, Florida • Hollywood, Florida + 16 more
- Conditions
- Influenza
- Interventions
- GSK2340274A, GSK2340273A
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 6 Months to 8 Years
- Enrollment
- 323 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 17
- States / cities
- Conway, Arkansas • Little Rock, Arkansas • Sacramento, California + 14 more
- Conditions
- Hematopoietic Cell Transplantation Recipient, Malignant Neoplasm, Influenza
- Interventions
- Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Laboratory Biomarker Analysis
- Biological · Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 9
- States / cities
- San Francisco, California • Kansas City, Missouri • Cincinnati, Ohio + 6 more
- Conditions
- Influenza
- Interventions
- Trivalent Inactivated Influenza Vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 35 Months
- Enrollment
- 243 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 7
- States / cities
- Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 3 more
- Conditions
- Melanoma (Skin Cancer), Advanced Melanoma, Metastatic Melanoma, Skin Cancer
- Interventions
- iSCIB1+, Nivolumab & Ipilimumab, Placebo
- Biological · Drug · Other
- Lead sponsor
- Scancell Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Pneumonia, Pneumococcal
- Interventions
- V116, QIV, Matching Placebo for V116
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,080 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 56
- States / cities
- Phoenix, Arizona • Canoga Park, California • La Mesa, California + 46 more
- Conditions
- COVID-19
- Interventions
- NVX-CoV2373, SARS-CoV-2 rS antigen/Matrix-M Adjuvant
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 5
- States / cities
- Austin, Texas • Fort Worth, Texas • Plano, Texas + 1 more
- Conditions
- Avian Influenza
- Interventions
- H5 AC-Anhui RNA Vaccine, H5 Astrakhan RNA Vaccine, Sodium Chloride, 0.9%
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- Durham, North Carolina • Nashville, Tennessee • Houston, Texas
- Conditions
- SARS-CoV-2 Infection, COVID-19, Maternal Immunization
- Interventions
- BNT162b2, Placebo
- Biological · Other
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 726 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 28 more
- Conditions
- HIV Infections
- Interventions
- HIV CTL MEP administered with RC529-SE adjuvant, GM-CSF
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2006
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 4 more
- Conditions
- Varicella, Rubella, Mumps, Measles
- Interventions
- Priorix-Tetra™ (MMRV vaccine 208136), ProQuad®, Havrix®, Prevnar®
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Months to 14 Months
- Enrollment
- 1,851 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 141
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 125 more